News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Giuseppe Caruso: 2024 – A Break through Year in Gynecologic Oncology
Giuseppe Caruso/X
Dec 27, 2024, 15:44

Giuseppe Caruso: 2024 – A Break through Year in Gynecologic Oncology

Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on X:

“2024: A Break through Year in Gynecologic Oncology.

With 6 new FDA-approved drugs/indications, we are entering a brighter future for patients battling gynecological malignancies.

Hope is stronger than ever.”

Giuseppe Caruso

For more updates, follow OncoDaily.

cancer Drugs FDA Giuseppe Caruso Gynecologic Oncology gynecological malignancies malignancies OncoDaily Oncology patients
Special Coverage
Blog
Jan 31, 2025, 22:43
Yakup Ergün: External-beam radiation versus TACE for HCC
Blog
Jan 31, 2025, 22:43
Mark Lewis: Running, walking, and crawling are all moving forward, just at different speeds
Insight
Jan 31, 2025, 22:43
Issa Mohamad: Survey of Current Practices for Early-Stage Glottic Squamous Cell Carcinoma
Blog
Jan 31, 2025, 22:43
Monika Pansari: Early detection saves lives
Blog
Jan 31, 2025, 22:43
Bhavin Vadodariya: Team work in cancer surgery
Blog
Jan 31, 2025, 22:43
Europe, the time is now: Liver health can’t wait - ELPA
Blog
Jan 31, 2025, 22:43
Wafaa Rashed: Honored to feature Catherine Metayer in this episode of the PAPERI Bright Minds Series
Blog
Jan 31, 2025, 22:43
The first outreach of the year took us to Stem Child Care Academy - Medicaid Cancer Foundation
Blog
Jan 31, 2025, 22:43
Olubukola Ayodele: Thankful to participate in the Cancer Symposium at the University of Leicester
Blog
Jan 31, 2025, 22:42
Transcriptional States and Dynamics of Circulating Tumor-Infiltrating Lymphocytes during Immunotherapy
Insight
Jan 31, 2025, 19:25
Tanja Obradovic: New Phase III trial with an innovative MOA may soon change the standard of care for second-line MSS CRC
Blog
Jan 31, 2025, 18:05
Shining a light on the EU-funded projects - Association of European Cancer Leagues